



Ovation Science Ships DermSafe Hand Sanitizer to China Collaboration Phase Entered for DermSafe

Vancouver, BC – August 27, 2020 (CSE: OVAT) – Ovation Science Inc. (“Ovation” or the “Company”) is pleased to announce that it has shipped DermSafe hand sanitizer in bulk supply of 200 kilograms to its distributor in Guangzhou, China. This shipment will help facilitate their development of a novel mechanism to dispense DermSafe using an individual use, unique delivery device. This relationship aims to advance the distribution of DermSafe into China, the world’s largest country with a population of 1.43 billion people.

This collaboration is the first phase for a potential distribution agreement to import DermSafe hand sanitizer into China once the delivery device has been designed and regulatory approval has been obtained. It also establishes a cooperative effort to conduct tests and exchange exploratory information in order to assess and develop their device which will provide a unique way to deliver DermSafe in packets as a single use. This preliminary shipment of DermSafe has been placed from Ovation’s recently announced Canadian production of DermSafe at its contract cGMP manufacturer in Ontario.

“We are excited to see the progress to develop a truly innovative mechanism to deliver and market DermSafe,” said Terry Howlett, President of Ovation. “This collaboration demonstrates our strong commitment to help fight this pandemic globally and to make a difference in people’s safety.” He further commented, “Previously we had shipped DermSafe to China under their “green channel” which temporarily facilitated the foreign exchange of goods related to the fight against this pandemic; however this has since closed. Should this collaboration progress into a distribution agreement, it is the Company’s intent to supply DermSafe manufactured in Canada in bulk to China.

The active ingredient in DermSafe, chlorhexidine gluconate, has been used in hospitals worldwide for over fifty years as a pre-surgical hand scrub due to its ability to kill both gram-negative and gram-positive bacteria and viruses. Furthermore, the Company also recently announced on July 8th, 2020 that DermSafe was successfully tested against human coronavirus (Surrogate to SARS-CoV-2; the virus that causes COVID-19), showing a 99.97% reduction in the virus at two time points. DermSafe does not contain alcohol and therefore is non-drying and does not have some of the issues that alcohol-based products do. Visit www.dermsafe.com for more information and to order.

Statements have not been evaluated by Health Canada. These products are not intended to diagnose, treat, cure, or prevent any disease.

For information about DermSafe and to purchase visit: <https://dermsafe.com>

For information about Ovation Science products visit: <https://ovationscience.com/products/>.

About Ovation Science Inc.

Ovation Science Inc. is a research and development company that develops topical and transdermal consumer products including DermSafe, all made with patented Invisicare® skin delivery technology. The technology

enhances the delivery of ingredients to and through the skin and is protected by patents in eleven countries. With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation's management and science team have created a unique pipeline of over twenty-five patent-protected medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from licensing and development fees, royalties, the sale of Invisicare to its licensees and now revenue from its own product sales. Ovation has offices in Vancouver, BC Canada and Las Vegas, Nevada, USA. Ovation trades on the CSE under the symbol **OVAT**. Visit our website www.ovationscience.com.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular there is no assurance of the development of a new delivery device, approval or future sales in China. There are no guarantees of future performance. Ovation Science Inc. cautions that all forward looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.'s control. Accordingly, readers should not place undue reliance on the forward-looking information. Ovation disclaims any obligation to revise or update any such forward-looking information to reflect future results, events or circumstances, except as required by law.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Contact:

INVESTOR RELATIONS:

Sebastian Kunyz: ovat@kincommunications.com Phone: 604-684-6730 or Toll Free at 866-684-6730

FOR BUSINESS DEVELOPMENT & CORPORATE INQUIRIES:

Doreen McMorran: doreen@ovationscience.com Phone: 604-283-0903 ext. 4